C2N Diagnostics has introduced a new Research Use Only (RUO) test to support the diagnosis and treatment of Alzheimer’s disease.

The high-resolution mass spectrometry-based plasma tau multi-analyte assay (p-tau MAA) uses a small sample of blood to determine different phosphorylated and non-phosphorylated forms of the tau protein.

It builds upon previous observations that complex interactions among abnormal tau and beta-amyloid proteins and other factors play a critical role in Alzheimer’s-related brain changes.

According to the company, the new test will provide researchers with an additional tool for studies of Alzheimer’s and brain health.

It is expected to help in identifying the underlying biological mechanisms of Alzheimer’s disease, as well as evaluating different ways to improve diagnosis of the condition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

C2N CEO and co-founder Dr Joel Braunstein said: “This development builds on our team’s history of providing exceptional laboratory services and products in the field of brain health. Our team has worked tirelessly to achieve this p-tau advancement that adds to our existing efforts to bring accurate, widely accessible and cost-effective blood tests to the clinic for the betterment of patient care.

“We look forward to sharing important data about the performance of our p-tau MAA test at upcoming medical meetings and in peer-reviewed publications.”

C2N currently offers the PrecivityAD test, which uses measurements of ApoE proteotype and the amyloid beta 42 and 40 peptides in plasma to determine the likelihood of amyloid plaques in an individual’s brain.

Researchers have found that this test can help diagnose Alzheimer’s disease among people with signs and symptoms of cognitive decline.